# Comparison of Tocilizumab Versus Tocilizumab/Infliximab in Patients With COVID-19-associated Cytokine Storm Syndrome

> **NCT04734678** · — · COMPLETED · sponsor: **Ain Shams University** · enrollment: 153 (actual)

## Conditions studied

- Covid19
- Cytokine Storm
- Corona Virus Infection

## Interventions

- **DRUG:** Tocilizumab
- **DRUG:** Infliximab

## Key facts

- **NCT ID:** NCT04734678
- **Lead sponsor:** Ain Shams University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-01
- **Primary completion:** 2021-06-01
- **Final completion:** 2021-08-01
- **Target enrollment:** 153 (ACTUAL)
- **Last updated:** 2022-07-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04734678

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04734678, "Comparison of Tocilizumab Versus Tocilizumab/Infliximab in Patients With COVID-19-associated Cytokine Storm Syndrome". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04734678. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*